Teva catches a downgrade from JPMorgan

• JPMorgan downgrades Teva (TEVA -1.4%) to Neutral from Overweight.
• A dramatic, near-term recovery for the drugmaker isn't likely, analyst Chris Schott suggests, and while the company could see "greater-than-anticipated EPS upside from cost-restructuring initiatives, near-term upside in either earnings or multiple," isn't likely.
• Price target cut to $43 from $45.